Skip to main content

Table 4 Samalizumab bound to CD200+ CLL cells by cohort

From: Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

Samalizumab Cohort

CLL cells bound by samalizumab (%)

Density of bound samalizumab (MFI)

Pre-dose

Day 1

Pre-dose

Day 1

50 mg/m2 (n = 4)

0.3–0.7

1.1–3.3

1.9–3.1

3.3–4.1

100 mg/m2 (n = 5)

0.2–2.4

0.2–9.5

3.5–5.6

5.0–11.1

200 mg/m2 (n = 2)

0.3–0.7

27.8–29.6

3.2–3.3

16.6–19.3

300 mg/m2 (n = 2)

0.5–0.7

5–28.6

1.7–3.0

5.6–16.8

400 mg/m2 (n = 3)

1.1–5.7

1.7–71.3

1.7–3.4

4.6–26.6

500 mg/m2 (n = 5)

0.5–2.1

1–47.0

1–3.7

1.9–17.6

  1. Binding of samalizumab to CD200 on circulating CLL cells was evaluated by multi-parametric flow cytometry using a fluorescently-labeled monoclonal antibody specific for samalizumab (7B8) together with a second anti-CD200 antibody (IB2) specific for an epitope of CD200 distinct from the binding site of samalizumab
Back to article page